Christian Rolfo

Citée par

	Toutes	Depuis 2020
Citations	27159	16070
indice h	70	59
indice i10	272	239

3300

1650

825

2475

2010201120122013201420152016201720182019202020212022202320242025222 323 456 757 902 1216 1417 1586 1725 2095 2618 3229 3299 3193 3186 487

Accès public

Tout afficher

74 articles

16 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Alessandro RussoMedical Oncology, Humanitas Istituto Clinico Catanese, Misterbianco, Catania, ItalyAdresse e-mail validée de humanitascatania.it
Oscar ArrietaMedical Oncology, Instituto Nacional de Cancerología de MexicoAdresse e-mail validée de unam.mx
Umberto MalapelleDepartment of Public Health, University Federico II of NaplesAdresse e-mail validée de unina.it
Elisa GiovannettiAssociate Professor - UHD - Amsterdam UMC (VUmc) & FPS, PisaAdresse e-mail validée de vumc.nl
Antonio RussoUniversity of PalermoAdresse e-mail validée de community.unipa.it
Filip LardonFull professor - Vice-rector, University of AntwerpAdresse e-mail validée de uantwerpen.be
Viviana BazanUniversity of PalermoAdresse e-mail validée de usa.net
Jan P van MeerbeeckUniversiteit Antwerpen - Universitair Ziekenhuis Antwerpen- Universiteit GentAdresse e-mail validée de uza.be
Julie JacobsUniversiteit AntwerpenAdresse e-mail validée de uantwerpen.be
Salvatore SienaUniversità degli Studi di Milano e Ospedale Niguarda, Milano, ItalyAdresse e-mail validée de unimi.it
Luis CorralesCIMCA / HSJD-CCSS Costa RicaAdresse e-mail validée de cimcacr.com
Pasquale PisapiaUniversity of Naples Federico IIAdresse e-mail validée de unina.it
Luis Leonardo Rojas PuentesCentro de tratamiento e investigación sobre cáncer (CTIC)Luis Carlos Sarmiento ÁnguloAdresse e-mail validée de fctic.org
GJ PetersProfessor of Pharmacology of Cytostatics, Amsterdam UMC, location VUMC, Amsterdam; and MedicalAdresse e-mail validée de amsterdamumc.nl
Laure SorberPhD, Oncology, Antwerp UniversityAdresse e-mail validée de uantwerpen.be
Christophe DebenPhDAdresse e-mail validée de uantwerpen.be
Rafael SireraProfessor of Cell BiologyAdresse e-mail validée de btc.upv.es
Joseph A. PintoOncosalud-AUNAAdresse e-mail validée de gecoperu.org
Eduardo CastanonColaborador Clínico Universidad de NavarraAdresse e-mail validée de unav.es
Paolo MancaResearch Scholar MSK - Oncology Resident INT MilanAdresse e-mail validée de mskcc.org

Suivre

Christian Rolfo

Professor in Oncology, Head of Phase I -Early Clinical Trials Unit, Oncology, Antwerp University

Adresse e-mail validée de uza.be

thoracic oncology liquid biopsies exosomes drug development clincial trials


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012	6497	2012
Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009	3046	2009
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018	651	2018
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ... The Lancet Oncology 20 (8), 1124-1135, 2019	514	2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020	475	2020
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021	465	2021
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target M Román, I Baraibar, I López, E Nadal, C Rolfo, S Vicent, I Gil-Bazo Molecular cancer 17, 1-14, 2018	356	2018
Impact of the COVID-19 pandemic on cancer care: a global collaborative study AR Jazieh, H Akbulut, G Curigliano, A Rogado, AA Alsharm, ED Razis, ... JCO global oncology 6, 1428-1438, 2020	279	2020
The role of nuclear factor-kappa B signaling in human cervical cancer S Tilborghs, J Corthouts, Y Verhoeven, D Arias, C Rolfo, XB Trinh, ... Critical reviews in oncology/hematology 120, 141-150, 2017	272	2017
FGFR a promising druggable target in cancer: Molecular biology and new drugs R Porta, R Borea, A Coelho, S Khan, A Araújo, P Reclusa, T Franchina, ... Critical reviews in oncology/hematology 113, 256-267, 2017	255	2017
A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma L Sorber, K Zwaenepoel, V Deschoolmeester, G Roeyen, F Lardon, ... The journal of molecular diagnostics 19 (1), 162-168, 2017	248	2017
RET fusions in solid tumors AY Li, MG McCusker, A Russo, KA Scilla, A Gittens, K Arensmeyer, ... Cancer treatment reviews 81, 101911, 2019	231	2019
Liquid biopsies in lung cancer: the new ambrosia of researchers C Rolfo, M Castiglia, D Hong, R Alessandro, I Mertens, G Baggerman, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 539-546, 2014	227	2014
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies N Boeckx, R Koukakis, KO De Beeck, C Rolfo, G Van Camp, S Siena, ... Annals of Oncology 28 (8), 1862-1868, 2017	210	2017
CD70: An emerging target in cancer immunotherapy J Jacobs, V Deschoolmeester, K Zwaenepoel, C Rolfo, K Silence, ... Pharmacology & therapeutics 155, 1-10, 2015	210	2015
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer U Malapelle, R Sirera, E Jantus-Lewintre, P Reclusa, S Calabuig-Fariñas, ... Expert review of molecular diagnostics 17 (3), 209-215, 2017	188	2017
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer A Leonetti, B Wever, G Mazzaschi, YG Assaraf, C Rolfo, F Quaini, M Tiseo, ... Drug Resistance Updates 46, 100644, 2019	187	2019
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges VSS Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C ... Nat Rev Clin Oncol, 2017	186	2017
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients L Sorber, K Zwaenepoel, V Deschoolmeester, PEY Van Schil, ... Lung cancer 107, 100-107, 2017	185	2017
Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy A Rodríguez-Martínez, D de Miguel-Pérez, FG Ortega, JL García-Puche, ... Breast Cancer Research 21, 1-9, 2019	178	2019

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs